Literature DB >> 3395999

Mechanism of cis-diamminedichloroplatinum(II)-induced cytotoxicity: role of G2 arrest and DNA double-strand breaks.

C M Sorenson1, A Eastman.   

Abstract

DNA has been implicated as the critical target for cis-diamminedichloroplatinum(II) (cis-DDP)-induced cytotoxicity. In vitro, DNA-platinum adducts inhibit DNA synthesis. An assessment of the inhibition of DNA synthesis in murine leukemia L1210 cells demonstrated that, although cell division was halted, DNA replication continued for a period of time. The DNA underwent almost a complete doubling even in cells that did not divide. Flow cytometric analysis demonstrated a slowed synthetic phase which progressed to a block in the G2 phase of the cell cycle. The duration of the G2 block was proportional to the concentration of cis-DDP. Low concentrations of cis-DDP caused the cells to be transiently blocked in the G2 phase for 24 to 48 h. Higher concentrations of cis-DDP resulted in a G2 arrest that was not reversed by 96 h. After this time, the arrested cells appeared to disintegrate, rather than recover. Cell survival and trypan blue exclusion studies indicated that, at low drug concentrations, cells which had transiently arrested in the G2 phase survived, while at higher concentrations only a limited number of survivors were responsible for the observed recovery of growth. Analysis of DNA double-strand breaks showed that significant numbers of breaks only occurred at concentrations of cis-DDP that subsequently led to debris detectable on the flow cytometer and to loss of trypan blue exclusion. The formation of these breaks appeared to be the first detectable change that was indicative of cell death. It is proposed that cells arrest in the G2 phase because they are unable to transcribe damaged DNA and make mRNA essential for passage into mitosis. DNA repair probably overcomes this arrest. Cell death may therefore be a consequence of the inability to adequately recover transcription.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3395999

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  69 in total

Review 1.  Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs.

Authors:  Xiangyi Lu; Li Xiao; Luan Wang; Douglas M Ruden
Journal:  Biochem Pharmacol       Date:  2011-11-22       Impact factor: 5.858

2.  RNA-Pt adducts following cisplatin treatment of Saccharomyces cerevisiae.

Authors:  Alethia A Hostetter; Maire F Osborn; Victoria J DeRose
Journal:  ACS Chem Biol       Date:  2011-11-15       Impact factor: 5.100

Review 3.  Third row transition metals for the treatment of cancer.

Authors:  Timothy C Johnstone; Kogularamanan Suntharalingam; Stephen J Lippard
Journal:  Philos Trans A Math Phys Eng Sci       Date:  2015-03-13       Impact factor: 4.226

4.  Cytoplasmic initiation of cisplatin cytotoxicity.

Authors:  Fang Yu; Judit Megyesi; Peter M Price
Journal:  Am J Physiol Renal Physiol       Date:  2008-04-09

5.  Pelvic irradiation modulates the pharmacokinetics of cisplatin in the plasma and lymphatic system.

Authors:  Tung-Hu Tsai; Yu-Jen Chen; Mei-Ling Hou; Li-Ying Wang; Hung-Chi Tai; Chen-Hsi Hsieh
Journal:  Am J Transl Res       Date:  2015-02-15       Impact factor: 4.060

6.  Non-traditional platinum compounds for improved accumulation, oral bioavailability, and tumor targeting.

Authors:  Katherine S Lovejoy; Stephen J Lippard
Journal:  Dalton Trans       Date:  2009-10-01       Impact factor: 4.390

7.  Complex cisplatin-double strand break (DSB) lesions directly impair cellular non-homologous end-joining (NHEJ) independent of downstream damage response (DDR) pathways.

Authors:  Catherine R Sears; John J Turchi
Journal:  J Biol Chem       Date:  2012-05-23       Impact factor: 5.157

8.  [1,2-Bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II), a new compound for the therapy of ovarian cancer. III. Detailed evaluation of the antitumor activity of the enantiomeric complexes on the human NIH:OVCAR-3 ovarian cancer cell line.

Authors:  G Bernhardt; R Gust; H Reile; H D vom Orde; R Müller; C Keller; T Spruss; H Schönenberger; T Burgemeister; A Mannschreck
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

9.  Monitoring of chemotherapy-induced morphonuclear modifications by means of digital cell-image analysis.

Authors:  O Pauwels; R Kiss
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

Review 10.  Chemotherapeutic drug resistance in the management of head and neck cancer.

Authors:  H Bier
Journal:  Eur Arch Otorhinolaryngol       Date:  1993       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.